Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
That holiday pedicure may leave you with hepatitis C

"In places like Bali, Thailand, Vietnam and the Philippines, hepatitis C can be nine or 10 times more prevalent than at home, and this coupled with generally lower standards of equipment sterilisation in the average tattoo parlour or where you get pedicures can greatly increase the risk of infection," Tyrell says.

Published
15 hours ago
From
Courier Mail
MSF urges BMS to make daclatasvir accessible in low-and middle-income countries

Welcoming the EMA's approval of daclatasvir on August 27, 2014, the MSF said that the BMS must rapidly register daclatasvir in those countries with a high burden of hepatitis C, especially in those countries with a high prevalence of genotype 3. It also urged BMS to ensure daclatasvir is affordable in those countries with a high burden of hepatitis C.

Published
15 hours ago
From
Pharmabiz
European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

Bristol-Myers Squibb Company today announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults. Daklinza, when used in combination with sofosbuvir (Sovaldi), is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials

Published
27 August 2014
From
Bristol-Myers Squibb
The Risky Business of Limiting Medicaid Access to Sovaldi

Partially because of its high cost, nearly half the states are restricting Medicaid patients' access to an effective new hepatitis C drug. Experts say there’s no question lawsuits will come.

Published
21 August 2014
From
Governing
Nearly Half of Surveyed US Specialists Expect to Prescribe Gilead's Sofosbuvir / Ledipasvir Regimen Near-Term for Hepatitis C Infections

Analysis of surveyed specialists' near-term prescribing intent indicates that nearly one in every four actively treated genotype 1 patients will be prescribed the sofosbuvir/ledipasvir regimen in the next six months. However, the on-treatment patient shares for the off-label Olysio (Janssen) and Sovaldi combination regimen are expected to remain stable over this period.

Published
21 August 2014
From
Decision Resources Group press release
Expanded harm reduction provision achieves impressive reductions in HCV incidence among PWID in Scotland

Implementation of comprehensive harm reduction policies has achieved impressive reductions in incidence of hepatitis C virus (HCV) infections among people who inject drugs (PWID) in Scotland, research published

Published
20 August 2014
By
Michael Carter
Britain Has No Problem Paying for Expensive Hepatitis C Drugs

The U.K.’s decision to recommend Sovaldi was far from a sure thing. But once the National Institute for Health and Care Excellence was convinced that Sovaldi is cost-effective, the decision to pay for it is simple, because one entity pays for all the medical care in the U.K. If treating a patient with costly drugs now prevents a more expensive liver transplant in 15 years, that savings accrues to the National Health Service—and ultimately to British taxpayers.

Published
19 August 2014
From
Businessweek
PegLambda discontinued by BMS

We have concluded that given the very promising developments in HCV in terms of emerging all-oral therapeutic options, Lambda would no longer fulfill the unmet need that we had envisioned upon initiation of the clinical trials.

Published
18 August 2014
From
EATG
Emergent HCV epidemic among young, non-urban people who inject drugs in the United States

Incidence of acute hepatitis C virus (HCV) infection increased significantly among young, non-urban people who inject drugs in the United States between 2006 and 2012, investigators report in

Published
18 August 2014
By
Michael Carter
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection.

Published
18 August 2014
From
Achillion press release
← First12345...101Next →

Filter by country